Biotechnology and Today's Warfighter
The Rand Blog
OCTOBER 25, 2022
Biotechnology has a broad and often misunderstood scope, one with significant implications for today's warfighter, and it may be reaching a critical junction.
Biotechnology Related Topics 
69 
Bill of Health’s Top 10 Posts of 2022
Bill of Health
DECEMBER 29, 2022
We look forward to continuing our coverage of key issues in health law policy, biotechnology, and bioethics in 2023. By Chloe Reichel. As 2022 draws to a close, we’re looking back at the top ten most-read articles published on Bill of Health this year. Browse the list below.
Join 13,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
In Academia, Innovators Receive Unfair Compensation for Their Discoveries
Bill Of Health
NOVEMBER 12, 2021
Biotechnology Intellectual Property Matt Bauer Research Funding patents universitiesBy Matt Bauer. In academia, many of the scientists who are recognized as inventors on patents see little economic gain from these agreements.
Decolonizing the Pandemic Treaty Through Vaccine Equity
Bill Of Health
OCTOBER 29, 2021
By Tlaleng Mofokeng, Daniel Wainstock, and Renzo Guinto. In recent years, there have been growing calls to “ decolonize ” the field of global health.
We All Stand to Benefit from Biden’s $2 Billion Bet on the Bioeconomy
Bill of Health
OCTOBER 10, 2022
Business is bustling for biotechnology and biomanufacturing. On September 12, 2022, President Biden signed an executive order , launching a “whole-of-government approach to advance biotechnology and biomanufacturing.” Biotechnology regulation. By Matthew Chun.
The Pandemic Treaty and Intellectual Property Sharing: Making Vaccine Knowledge a Public Good
Bill Of Health
OCTOBER 15, 2021
By Ellen ‘t Hoen. The COVID-19 pandemic has laid bare the lack of regulation for the sharing of intellectual property (IP) and technology needed for an effective and equitable response to the crisis.
Visualizing the Growing Intersection of Life Sciences and Computing Patents in the US from 1976-2021
Bill of Health
JANUARY 24, 2023
By Matthew Chun With its leadership in drug development , biotechnology , and computing technologies , the United States touts itself as being “ the most innovative economy in the world.” biotechnology, President Biden also recognized that “ fundamental R&D of emerging biotechnologies.
Promoting Vaccine Equity
Bill Of Health
OCTOBER 13, 2021
By Ana Santos Rutschman. The COVID-19 pandemic has brought into sharp relief longstanding equity problems surrounding the allocation of newly developed vaccines against emerging pathogens.
Does It Really Matter How the COVID-19 Pandemic Started?
Bill of Health
JANUARY 23, 2023
By Barbara Pfeffer Billauer Throughout the COVID-19 pandemic, much air time and social media space has been allocated to the lab leak vs. natural spillover dispute regarding the origins of SARS-CoV-2.
Leverage COVID-19 Frameworks to Prepare for the Next Pandemic
Bill Of Health
DECEMBER 8, 2021
Biotechnology Health Law Policy International Pharmaceuticals Public Health Research Funding Resource Allocation Vaccines COVID covid boosters covid pandemic infectious disease infectious disease surveillance mers pandemic preparedness pandemic prevention pandemic response sars SARS-CoV-2
The Not-So-Sacred Human Genome: What South Africans Think About Heritable Human Genome Editing
Bill of Health
DECEMBER 2, 2022
Bioethics Biotechnology Enhancement Genetics International Personhood AIDS Gene editing heritable human genome editing HIV HIV/AIDS human genome human genome editing south africa tb tuberculosisBy Donrich Thaldar.
The International Weaponization of Health Data
Bill of Health
OCTOBER 18, 2022
By Matthew Chun. International collaboration through the sharing of health data is crucial for advancing human health. But it also comes with risks — risks that countries around the world seem increasingly unwilling to take.
The ‘Res Nullius’ Construction of Human Genomic Data
Bill of Health
NOVEMBER 21, 2022
Biotechnology Genetics Intellectual Property International Privacy data genomic data property law res nulliusBy Donrich Thaldar. No one domain of the law holds exclusive sway over human genomic data.
No Take-Backs: Moderna’s Attempt to Renege on its Vaccine Patent Pledge
Bill of Health
AUGUST 29, 2022
IBM and Google) to biotechnology (e.g., Biotechnology Featured Health Law Policy Intellectual Property Jorge Contreras Public Health Vaccines compulsory licensing COVID-19 covid-19 vaccine Health Resources moderna Open COVID pledge patent Patent Law patent pledge patentsBy Jorge L.
A New Theory for Gene Ownership
Bill of Health
AUGUST 31, 2022
Without her knowledge or consent, her doctors derived from the cells the HeLa cell line — the world’s first immortal human cell line, worth billions and a driver of the biotechnology revolution. By James Toomey.
Book Review: ‘Drugs and the FDA: Safety, Efficacy, and the Public’s Trust’ by Mikkael A. Sekeres
Bill of Health
NOVEMBER 9, 2022
Bioethics Biotechnology FDA FDA in the 21st Century Conference Matthew Chun Medical Safety Pharmaceuticals access to medicine Book Review drug law drug regulation Patient autonomy pharmaceuticalBy Matthew Chun.
Another Legislative Attempt to Revive Gene Patenting
Bill of Health
AUGUST 4, 2022
Not surprisingly, some representatives of the biotechnology industry, and many patent lawyers, reacted negatively to the decision, and have steadily lobbied Congress to restore patent protection for isolated and purified genomic sequences. Biotechnology Gene Editing Genetics Jorge Contreras
Biotech Companies Are Opening Manufacturing Sites in Africa: Will This Help Vaccine Equity?
Bill of Health
JANUARY 17, 2023
Biotechnology Global Health Intellectual Property International Pharmaceuticals Public Health Race Resource Allocation Sarah Gabriele Student Fellows Vaccines africa biontech COVID covid pandemic covid-19 vaccines global vaccine inequity know-how moderna vaccine equityBy Sarah Gabriele.
AI in Digital Health: Autonomy, Governance, and Privacy
Bill of Health
NOVEMBER 10, 2022
Artificial Intelligence Biotechnology Digital Health Health Information Technology Medical devices Patient Care Privacy Publications AI algorithms data privacy EthicsThe following post is adapted from the edited volume AI in eHealth: Human Autonomy, Data Governance and Privacy in Healthcare.
Mainstreaming Reproductive Genetic Innovation
Bill of Health
DECEMBER 14, 2022
By Myrisha S. Lewis. Despite religious and ethical objections, assisted reproductive technology (ART), including in vitro fertilization and egg freezing, manages to flourish in the United States, with some states and companies even creating regimes for its insurance coverage.
Pig Hearts for Humans and the FDA
Bill of Health
APRIL 14, 2022
Animal Research Biotechnology FDA Health Law Policy Organs Public Health Resource Allocation Organ Transplantation organ transplants xenotransplantationBy Jacob Balamut.
Reclaiming Global Public Health
Bill of Health
SEPTEMBER 20, 2022
By Zain Rizvi. By December 2020, the world had astonishingly powerful tools against COVID-19. New mRNA vaccines, underpinned by decades of public investment , had been authorized by global regulators.
The Legality of Pandemic Detection and Prevention Technology
Bill Of Health
AUGUST 9, 2021
Biotechnology Global Health Health Law Policy Public Health Scientific Evidence commerce clause coronavirus pandemic COVID-19 covid-19 pandemic COVID19 isolation medical isolation laws novel pathogens pandemic detection pandemic prevention pathogens quaratine Tenth Amendment test-and-isolate
COVID-19, Patents, and Trade Secrets
Bill of Health
JUNE 22, 2022
Biotechnology Intellectual Property Pharmaceuticals Vaccines covid vaccine covid-19 vaccine IP moderna moderna covid vaccine moderna covid-19 vaccine patent Pfizer trade secretBy David Gindler & Jasper L. Has the worldwide distribution of COVID-19 vaccines been impacted by patent rights?
Accessing COVID-19 mRNA Vaccines for Research: The Re-emergence of the Tragedy of the ‘Anticommons’
Bill of Health
OCTOBER 31, 2022
This problem is not new in the biotechnology sector. By Aparajita Lath.
Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna?
Bill of Health
JANUARY 6, 2022
Biotechnology Featured Genetics Health Information Technology History Intellectual Property Jorge Contreras Research Funding Scientific Evidence Supreme Court Vaccines aclu Association for Molecular Pathology v. By Jorge L. Contreras.
A Response to ‘Another Legislative Attempt to Revive Gene Patenting’
Bill of Health
AUGUST 26, 2022
Myriad Genetics could boost investment in biotechnology R&D. Biotechnological innovations also face resource-intensive and risky development cycles. Biotechnology Gene Editing Genetics Pharmaceuticals Supreme Court Association for Molecular Pathology v.
COVID ‘Compromise’ on International IP Underscores Need for New Approach
Bill of Health
APRIL 6, 2022
By Cynthia M.
Get Your Story Straight: Patent Office Cracks Down on Inconsistent Statements Made Before the FDA
Bill of Health
SEPTEMBER 29, 2022
For example, while a biotechnology company might be incentivized to claim the similarity of its products to already approved products to benefit from expedited FDA clearance (e.g., By Matthew Chun.
The Risk of Pervasive Trade Secret Practices Within the Life Sciences
Bill of Health
FEBRUARY 18, 2022
Biotechnology Health Law Policy Intellectual Property Matt Bauer biologics Biosimilars patents Trade SecretsBy Matt Bauer.
The Journal of Law and the Biosciences’ Growing Impact
Bill of Health
JULY 28, 2022
Announcements Bioethics Biotechnology Health Law Policy Petrie-Flom Center Public Health Abortion choice of law dobbs Dobbs v.
Lessons Learned from the COVID-19 Pandemic: The Future for Diagnostics
Bill of Health
APRIL 15, 2022
Biotechnology CRISPR Matt Bauer Medical devices Public Health COVID-19 diagnostic tests Diagnostics mCARMEN pandemic pandemic diagnostics pcr rapid antigen testsBy Matthew Bauer and Nicole Welch. Diagnostic tests have changed in the eyes of many Americans across the COVID-19 pandemic.
Using Contracts to Lessen Inequities in Access to Medicines in Pandemics and Epidemics
Bill of Health
MARCH 24, 2022
At the research and development (R&D) stage, government funders can bind producers to equity goals through targeted contractual provisions, as we explain in a recently-published Nature Biotechnology article. By Sapna Kumar and Ana Santos Rutschman.
Call for Submissions: Journal of Law and the Biosciences Special Issue on Abortion Law
Bill Of Health
NOVEMBER 16, 2021
Announcements Bioethics Biotechnology Call for Abstracts Health Law Policy Petrie-Flom Center Public Health Publications Journal of Law and the Biosciences The Journal of Law and the BiosciencesAmerican law on reproduction seems likely to change, perhaps radically, in 2022, as the U.S.
Access-to-Medicines Activists Demand Health Justice During COVID-19 Pandemic
Bill Of Health
AUGUST 12, 2021
By Brook K. Baker .
The Civil Rights Challenge to Gene Patenting
Bill Of Health
OCTOBER 19, 2021
Myriad Genetics that naturally occurring DNA sequences are not patentable, a ruling that has had repercussions throughout the scientific community and the biotechnology industry. Register now for tomorrow’s discussion of The Genome Defense ! By Jorge L. Contreras.
Call for Submissions: Journal of Law and the Biosciences Special Issue on Abortion Law
Bill of Health
JANUARY 21, 2022
Announcements Bioethics Biotechnology Call for Abstracts Health Law Policy Petrie-Flom Center Public Health Publications Journal of Law and the Biosciences The Journal of Law and the BiosciencesAmerican law on reproduction seems likely to change, perhaps radically, in 2022, as the U.S.
ChristianaCare Spins Out New Gene Editing Company, CorriXR Therapeutics
HIT Consultant
OCTOBER 13, 2022
What You Should Know: – ChristianaCare recently announced it has spun out its first commercial biotechnology private startup company, named CorriXR Therapeutics. The CorriXR Therapeutics team includes experienced biotechnology executives and world-renowned scientists and clinicians.
Vevo Launches with $12M to Scale Vivo Data Generation to Discover Better Drugs
HIT Consultant
DECEMBER 8, 2022
What You Should Know: – Vevo Therapeutics , an SF-based biotechnology company, launched today with a $12M seed round led by General Catalyst and Wing Venture Capital using its Mosaic in vivo drug discovery platform and next-generation AI models to uncover better drugs for more patients.
Biotech R&D Platform Benchling Closes $100M at $6B Valuation
HIT Consultant
NOVEMBER 18, 2021
Benchling’s growth is fueled by the rapid rise of biotechnology , one of the world’s fastest-growing industries. Biotechnology is rewriting life as we know it.
JPMorgan Establishes Life Sciences Private Equity Division
HIT Consultant
NOVEMBER 2, 2022
What You Should Know: – J.P. Morgan Asset Management announced the establishment of a new life sciences private equity team, Life Sciences Private Capital.
Biotech Startup Obatala Sciences Raises $3M for Organ-on-a-Chip for Research
HIT Consultant
OCTOBER 14, 2022
Obatala Sciences, a New Orleans biotechnology company, was founded in 2017 to enable diversity in clinical research and speed up the development of better therapies for diseases like obesity, diabetes, and cancer, and advance research in tissue engineering and regenerative medicine.
CareMetx Acquires Patient Adherence Platform Human Care Systems
HIT Consultant
JANUARY 3, 2022
HCS), a company focused on helping patients adhere to and benefit from pharmaceutical and biotechnology products. What You Should Know: – Strategic acquisition of leading patient adherence technology and services provider to complement CareMetx current suite of patient access products.
Let's personalize your content